PMN vs. APLM, XLO, UNCY, LEXX, MRKR, EYEN, VYNE, ACXP, CARA, and BCTX
Should you be buying ProMIS Neurosciences stock or one of its competitors? The main competitors of ProMIS Neurosciences include Apollomics (APLM), Xilio Therapeutics (XLO), Unicycive Therapeutics (UNCY), Lexaria Bioscience (LEXX), Marker Therapeutics (MRKR), Eyenovia (EYEN), VYNE Therapeutics (VYNE), Acurx Pharmaceuticals (ACXP), Cara Therapeutics (CARA), and BriaCell Therapeutics (BCTX). These companies are all part of the "pharmaceutical preparations" industry.
Apollomics (NASDAQ:APLM) and ProMIS Neurosciences (NASDAQ:PMN) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, media sentiment, dividends, community ranking, institutional ownership, risk, valuation, analyst recommendations and earnings.
Apollomics received 2 more outperform votes than ProMIS Neurosciences when rated by MarketBeat users. However, 100.00% of users gave ProMIS Neurosciences an outperform vote while only 80.00% of users gave Apollomics an outperform vote.
Apollomics currently has a consensus price target of $2.00, suggesting a potential upside of 444.51%. ProMIS Neurosciences has a consensus price target of $8.00, suggesting a potential upside of 323.28%. Given ProMIS Neurosciences' higher possible upside, equities research analysts plainly believe Apollomics is more favorable than ProMIS Neurosciences.
19.1% of Apollomics shares are held by institutional investors. Comparatively, 50.1% of ProMIS Neurosciences shares are held by institutional investors. 10.3% of ProMIS Neurosciences shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
In the previous week, Apollomics had 4 more articles in the media than ProMIS Neurosciences. MarketBeat recorded 7 mentions for Apollomics and 3 mentions for ProMIS Neurosciences. Apollomics' average media sentiment score of 0.96 beat ProMIS Neurosciences' score of 0.40 indicating that ProMIS Neurosciences is being referred to more favorably in the news media.
ProMIS Neurosciences has lower revenue, but higher earnings than Apollomics.
Apollomics has a beta of 1.5, meaning that its share price is 50% more volatile than the S&P 500. Comparatively, ProMIS Neurosciences has a beta of 0.67, meaning that its share price is 33% less volatile than the S&P 500.
Summary
ProMIS Neurosciences beats Apollomics on 7 of the 13 factors compared between the two stocks.
Get ProMIS Neurosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PMN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PMN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProMIS Neurosciences Competitors List
Related Companies and Tools
